Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betamethasone local injection versus systemic methotrexate + prednisolone for idiopathic granulomatous mastitis
IRCT20200608047694N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of betamethasone, methotrexate and prednisolone in Granulomatous lobular mastitis (GLM) (3 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Disappearance of inflammatory signs, closure of fistula orifices, and skin erosions. Started May 2020; status: completed.
02
Drugs
betamethasonemethotrexateprednisolone
03
Conditions
Granulomatous lobular mastitis (GLM)
Beyond the preview
Go deeper on IRCT20200608047694N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200608047694N1.